Isavuconazole and Liposomal Amphotericin B as Successful Combination Therapy of Refractory Invasive Candidiasis in a Liver Transplant Recipient: A Case Report and Literature Review

Mycopathologia. 2022 Feb;187(1):113-120. doi: 10.1007/s11046-021-00599-1. Epub 2021 Oct 31.

Abstract

Invasive fungal infections in liver transplant recipients are associated with elevated morbidity and mortality and pose a challenge to the treating physicians. Despite of lacking clinical data, the use of antifungal combination therapy is often considered to improve response rates in an immunocompromised patient population. We herein report a case of refractory invasive candidiasis in a liver transplant recipient treated successfully with a combination of isavuconazole und high-dose liposomal amphotericin B. The antimycotic combination treatment was able to clear a bloodstream infection with C. glabrata and led to regression of bilomas among tolerable side effects. The use of the above-mentioned antifungal combination therapy in a liver transplant recipient has not been reported previously. This case highlights the efficacy and safety of antifungal combination therapy in immunocompromised patients with refractory invasive candidiasis.

Keywords: Antifungal combination therapy; Candidemia; Invasive candidiasis; Isavuconazole; Liposomal amphotericin B; Liver transplantation.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Amphotericin B
  • Antifungal Agents / therapeutic use
  • Candidiasis, Invasive* / diagnosis
  • Candidiasis, Invasive* / drug therapy
  • Humans
  • Liver Transplantation*
  • Nitriles
  • Pyridines
  • Triazoles

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • liposomal amphotericin B
  • isavuconazole
  • Amphotericin B